Day One Biopharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Day One Biopharmaceuticals Inc (DAWN) is expected to report an earnings loss of 16 cents per share. This information comes from a Refinitiv Reuters earnings preview. The article provides a brief outlook on the company's anticipated financial performance.
Michael Vasconcelles Sells 2,728 Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) Stock
Michael Vasconcelles, an insider at Day One Biopharmaceuticals (NASDAQ:DAWN), sold 2,728 shares of the company's stock for $31,644.80, reducing his stake by 38.29%. This sale, along with sales by the CEO and CFO on the same day, indicates broad insider selling. Despite positive technical indicators and a consensus "Moderate Buy" rating from analysts, there are warnings about near-term earnings risk for the company.
Day One Biopharmaceuticals (NASDAQ:DAWN) Insider Lauren Merendino Sells 5,814 Shares
Lauren Merendino, an insider at Day One Biopharmaceuticals (NASDAQ:DAWN), sold 5,814 shares at an average price of $11.60, reducing her stake by 8.81%. Despite this insider sale, institutional ownership remains high at 87.95%, with several funds increasing their positions in Q4. Analysts maintain a generally positive outlook, assigning an average target price of $25.71 against the current share price of $11.56.
Will Day One Biopharmaceuticals, Inc. (DAWN) report negative earnings next week? What you should know
This article discusses the anticipation of Day One Biopharmaceuticals, Inc. (DAWN) reporting negative earnings next week. It likely delves into analyst expectations, financial forecasts, and key factors that could influence the upcoming earnings report, offering insights for investors.
Will Day One Biopharmaceuticals, Inc. (DAWN) Report Negative Earnings Next Week? What You Should Know
Day One Biopharmaceuticals (DAWN) is expected to report an increase in earnings and revenues for the quarter ended December 2025. While analysts anticipate a quarterly loss of $0.17 per share and revenues of $48.22 million, the company's Zacks Earnings ESP of -29.00% suggests that analysts have recently become more bearish on its prospects. Despite a strong Zacks Rank, this combination makes it difficult to definitively predict an earnings beat.
Day One Biopharmaceuticals (DAWN) Projected to Post Earnings on Tuesday
Day One Biopharmaceuticals (NASDAQ:DAWN) is expected to announce its Q4 2025 earnings before market open on Tuesday, February 24, 2026, with analysts forecasting a loss of ($0.15) per share. The stock opened at $11.35, and institutional investors own approximately 87.95% of the company's stock. Analysts currently have a "Moderate Buy" rating with a consensus price target of $25.71.
Day One Biopharmaceuticals, Inc. (DAWN): Analyst Ratings Suggest 110% Upside Potential
Day One Biopharmaceuticals, Inc. (DAWN) is a commercial-stage biotech company focusing on developing therapies for childhood and adult diseases, with promising candidates in clinical trials. Analysts show strong confidence in DAWN, with a consensus suggesting a 110% upside potential and an average price target of $23.13. Despite current unprofitability and negative financial metrics typical of a growth-stage biotech, the company's strong pipeline and analyst support indicate potential for significant future returns.
Understanding Momentum Shifts in (DAWN)
This article analyzes Day One Biopharmaceuticals Inc. (NASDAQ: DAWN), highlighting a positive near-term sentiment amidst a potential mid-term weak bias within a long-term strength context. It details a strong risk-reward short setup and outlines three trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, based on AI-generated signals for different time horizons.
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
Day One Biopharmaceuticals announced it will host a conference call and webcast on Tuesday, February 24, 2026, at 4:30 p.m. ET to report its financial results and discuss corporate progress for the fourth quarter and full-year 2025. The company specializes in developing targeted therapies for life-threatening diseases, particularly pediatric cancer, and its pipeline includes tovorafenib (OJEMDA™), DAY301, and Emi-Le (emiltatug ledadotin) following the acquisition of Mersana Therapeutics. An archived version of the webcast will be available for replay for 30 days.
Wall Street Analysts See a 101.08% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
Day One Biopharmaceuticals (DAWN) recently closed up 26.1% over four weeks, and Wall Street analysts project a mean price target of $22.44, suggesting a 101.1% upside. While analyst price targets can be misleading due to potential biases, increasing optimism about DAWN's earnings prospects, supported by upward EPS estimate revisions and a Zacks Rank #2 (Buy), suggests a legitimate reason for potential stock upside. Investors are cautioned to treat price targets with skepticism but consider the strong agreement in earnings estimate revisions as a positive indicator.
Wall Street Analysts See a 101.08% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
Day One Biopharmaceuticals (DAWN) recently closed at $11.16, with Wall Street analysts setting a mean price target of $22.44, suggesting a 101.1% upside. While impressive, the article cautions against relying solely on price targets due to potential analyst bias, emphasizing that earnings estimate revisions offer a more reliable indicator of potential stock movement. DAWN's current Zacks Rank #2 (Buy) and significant positive EPS estimate revisions support an optimistic outlook for the stock.
AlphaQuest LLC Has $1.30 Million Stock Holdings in Day One Biopharmaceuticals, Inc. $DAWN
AlphaQuest LLC significantly increased its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 1,065.6% in Q3, now holding 185,006 shares valued at $1.30 million. Despite strong institutional investment, the company faces insider selling and a Q3 revenue decline of 57.6% year-over-year, though it surpassed EPS estimates. Analysts maintain a "Moderate Buy" rating with a consensus target price of $25.71.
Avoiding Lag: Real-Time Signals in (DAWN) Movement
The article provides a real-time stock analysis for Day One Biopharmaceuticals Inc. (NASDAQ: DAWN), noting conflicting sentiment across different time horizons and suggesting choppy conditions with elevated downside risk. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop loss points, and offers a multi-timeframe signal analysis.
Day One Biopharmaceuticals (NASDAQ:DAWN) Upgraded to Strong-Buy at Zacks Research
Zacks Research has upgraded Day One Biopharmaceuticals (NASDAQ:DAWN) from a "hold" to a "strong-buy" rating. This upgrade comes as the company holds a "Moderate Buy" consensus rating from analysts with a target price of $25.71, despite recent insider share sales and negative financial margins. The stock shows high institutional ownership with hedge funds increasing positions, even as it reported a 57.6% year-over-year revenue decrease last quarter.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Day One Biopharmaceuticals (NASDAQ: DAWN) has received a "Moderate Buy" consensus recommendation from analysts, with an average 1-year price target of $25.71. Despite recent insider selling and a significant year-over-year revenue decline, the company successfully beat its latest quarterly earnings and revenue estimates. Institutional investors hold a substantial 87.95% of the stock.
New Strong Buy Stocks for January 27th
Zacks Equity Research has identified five stocks as "Strong Buys" for January 27th, adding them to the Zacks Rank #1 List. These companies include Sandisk Corporation (SNDK), Steven Madden, Ltd. (SHOO), Day One Biopharmaceuticals, Inc. (DAWN), Enerflex Ltd. (EFXT), and Microchip Technology Incorporated (MCHP), all of which have seen significant increases in their Zacks Consensus Estimate for current or next year earnings over the last 60 days. Investors can access a complete list of these top-ranked stocks and additional investment recommendations from Zacks Investment Research.
Assessing Day One Biopharmaceuticals (DAWN) Valuation After Strong OJEMDA Revenue Update And 2026 Growth Outlook
Day One Biopharmaceuticals (DAWN) is under investor scrutiny following strong preliminary 2025 OJEMDA revenue figures and optimistic 2026 guidance, projecting 53% year-over-year growth. Despite a recent surge in share price, its Price-to-Sales ratio presents a mixed valuation picture: a discount to the broader US biotech industry but more expensive compared to closer peers. While the P/S is deemed "about right" by Simply Wall St's analysis, a Discounted Cash Flow model suggests a significant undervaluation, prompting investors to consider which valuation approach to prioritize for this loss-making biotech.
AIGH Capital Management LLC Makes New Investment in Day One Biopharmaceuticals, Inc. $DAWN
AIGH Capital Management LLC has made a significant new investment in Day One Biopharmaceuticals (NASDAQ:DAWN), acquiring 1,520,492 shares valued at approximately $10.72 million. This move, representing 1.48% of Day One Biopharmaceuticals and 3.0% of AIGH's portfolio, coincides with increased institutional interest from major firms like Millennium and Goldman Sachs, with institutional investors now owning 87.95% of DAWN stock. Despite a year-over-year revenue decline, Day One Biopharmaceuticals slightly exceeded Q3 earnings expectations, while insider selling and a "Moderate Buy" consensus analyst rating with an average target of $25.71 also characterize recent activity.
Discipline and Rules-Based Execution in DAWN Response
This article provides an AI-generated analysis for Day One Biopharmaceuticals Inc. (NASDAQ: DAWN), highlighting strong near and mid-term sentiment which could extend to the long term, despite elevated downside risk due to a lack of additional long-term support signals. It outlines three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels. The report emphasizes positive sentiment prevailing and offers access to real-time signals and personalized alerts.
Optimistic Investors Push Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Up 31% But Growth Is Lacking
Day One Biopharmaceuticals (NASDAQ:DAWN) shares have recently surged by 31%, bringing the stock back to its year-ago level. Despite this positive momentum, the company's price-to-sales (P/S) ratio of 9.3x is considered moderate compared to the biotech industry's median of 11.4x, especially given its sluggish past revenue growth. Analysts project a 45% annual revenue growth for Day One Biopharmaceuticals over the next three years, which is significantly lower than the industry forecast of 126%, suggesting that the current P/S might not be justified and shareholders could face future disappointment.
'Follow The Money,' Not The Tariff Noise, Says Expert, Spotlights This New S&P Data Center Cooling Stock Among Top Picks
Kevin Mahn, CIO at Hennion & Walsh Asset Management, advises investors to ignore tariff-related market noise and focus on long-term investment themes like the AI boom. He highlights data center cooling companies like Comfort Systems USA, utilities such as Duke Energy, and sectors like aerospace and defense, and small-cap biotech as promising opportunities. Mahn's strategy emphasizes following underlying growth trends and aligning with risk tolerance, even amidst market volatility.
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 7.6% - Time to Buy?
Day One Biopharmaceuticals (NASDAQ:DAWN) saw its share price increase by 7.6% on Tuesday, trading at $10.9290 on lower-than-average volume. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $25.71. Despite beating Q3 EPS and revenue estimates, the company's revenue declined 57.6% year-over-year, and it has negative margins and return on equity, while insiders have recently sold shares.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Up 19.2% in December
Day One Biopharmaceuticals (NASDAQ:DAWN) experienced a 19.2% increase in short interest in December, reaching 11,178,279 shares, which accounts for 11.6% of its stock. Despite significant insider selling and negative EPS, analysts maintain a "Moderate Buy" rating with an average target price of $25.71, well above its current trading price of $10.16. Institutional investors hold a substantial 87.95% of the company's stock.
First Week of March 20th Options Trading For Day One Biopharmaceuticals (DAWN)
New options contracts for Day One Biopharmaceuticals (DAWN) with a March 20th expiration date have begun trading. An analysis for a covered call strategy at the $11.00 strike price suggests a potential 4.03% return if the stock is called away, or a 0.94% boost if the option expires worthless, considering a premium to the current trading price. The article highlights the importance of reviewing the company's trading history and business fundamentals before engaging in such options strategies.
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 107.36%: Read This Before Placing a Bet
Day One Biopharmaceuticals (DAWN) stock has gained 22.5% in the past four weeks, closing at $10.73, and Wall Street analysts project a potential upside of 107.4% with a mean price target of $22.25. While price targets alone are not conclusive, a positive trend in earnings estimate revisions and a Zacks Rank #2 (Buy) suggest potential for an upside. Investors are advised to use price targets cautiously and consider other factors like analysts' agreement on earnings prospects.
Day One Biopharmaceuticals (DAWN) Is Up 11.7% After Strong OJEMDA 2025 Sales And 2026 Outlook - Has The Bull Case Changed?
Day One Biopharmaceuticals (DAWN) reported strong preliminary unaudited 2025 net product revenue of approximately US$155.4 million for OJEMDA and guided 2026 U.S. OJEMDA revenue to a US$225-250 million range. This performance solidifies OJEMDA as the company's primary growth driver while it expands its oncology portfolio. Despite the positive outlook, the article highlights the continued concentration of the company's revenue on a single drug as a key risk for investors to consider.
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 107.36%: Read This Before Placing a Bet
Day One Biopharmaceuticals (DAWN) has seen its shares gain 22.5% recently, with Wall Street analysts projecting a potential upside of 107.4% based on an average price target of $22.25. While price targets should be treated with skepticism due to potential biases, the company's strong earnings estimate revisions and a Zacks Rank #2 (Buy) suggest a legitimate upside. Investors are advised to consider these factors beyond just the consensus price target.
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Down 10.1% - What's Next?
Day One Biopharmaceuticals (NASDAQ:DAWN) experienced a 10.1% drop in its share price, trading down to $10.19 on above-average volume. Despite this decline, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $25.71. The company's latest quarterly earnings beat estimates but revenue decreased year-over-year, and it continues to operate unprofitably, with significant insider selling also noted.
A Look At Day One Biopharmaceuticals (DAWN) Valuation After Strong OJEMDA Revenue And 2026 Outlook Updates
Day One Biopharmaceuticals (DAWN) recently reported strong preliminary 2025 OJEMDA net product revenue of US$155.4 million and updated 2026 sales guidance, impacting its stock valuation. Despite a 51.60% decline in shareholder return over three years, recent news has led to a significant short-term share price increase. Analysts currently view the stock as undervalued, with a fair value estimate of US$22.25 against a closing price of US$11.33, implying potential upside based on future growth and profitability.
Day One Biopharmaceuticals stock initiated with Buy rating at TD Cowen
TD Cowen has initiated coverage on Day One Biopharmaceuticals (NASDAQ:DAWN) with a Buy rating and a $34.00 price target, citing significant upside potential from the current share price. This decision follows Day One Biopharmaceuticals' recent acquisition of Mersana Therapeutics and positive three-year follow-up data for its OJEMDA drug from the Phase 2 FIREFLY-1 trial. The company also forecasted strong net product revenue for OJEMDA for 2025 and 2026.
Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains?
Day One Biopharmaceuticals (DAWN) recently saw its shares surge 26.7% after reporting strong preliminary sales for its drug Ojemda for Q4 and full-year 2025. The company expects significant revenue growth for Ojemda in 2026, though its stock currently holds a Zacks Rank #3 (Hold) with unchanged consensus EPS estimates. This surge is attributed to higher trading volume and promising revenue forecasts for its lead drug.
DAWN: OJEMDA's growth and new pipeline assets set the stage for significant revenue expansion in 2026
Day One Biopharmaceuticals (DAWN) is poised for significant revenue expansion in 2026, driven by the rapid adoption and growing revenue of OJEMDA. The company is expanding OJEMDA into frontline pLGG and global markets, while also strengthening its pipeline through the Emmy Lee acquisition and progress with DAY301. Key data updates regarding its pipeline assets are expected in 2026.
Day One Announces Preliminary 2025 OJEMDA™ Net Product
Day One Biopharmaceuticals announced preliminary unaudited 2025 OJEMDA™ net product revenue of $155.4 million, representing 172% year-over-year growth, and provided 2026 U.S. net product revenue guidance of $225 - $250 million. The company also outlined key corporate priorities for 2026, including expanding OJEMDA's commercial opportunity, advancing pipeline programs like Emi-Le and DAY301, and completing enrollment in the pivotal Phase 3 FIREFLY-2 clinical trial. These updates precede their presentation at the J.P. Morgan Healthcare Conference.
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
Day One Biopharmaceuticals reported preliminary unaudited 2025 OJEMDA net product revenue of $155.4 million, representing 172% year-over-year growth, and projected 2026 U.S. net product revenue to be between $225 million and $250 million. The company is set to present these updates and its 2026 corporate priorities at the J.P. Morgan Healthcare Conference, focusing on increasing OJEMDA adoption, global expansion, advancing pipeline programs like Emi-Le and DAY301, and completing the FIREFLY-2 trial.
Day One Biopharmaceuticals stock soars after strong 2025 revenue forecast By Investing.com
Day One Biopharmaceuticals saw its stock rise significantly after forecasting strong net product revenue for its OJEMDA drug in 2025 and 2026, driven by increased patient demand. The company also announced strategic corporate priorities for 2026, including expanding OJEMDA's commercial reach globally and advancing its pivotal Phase 3 FIREFLY-2 clinical trial. These updates were provided ahead of its presentation at the J.P. Morgan Healthcare Conference.
Day One Biopharmaceuticals Reports 172% Year-over-Year Growth in 2025 Net Product Revenue, Projects 2026 Revenue Between $225 Million and $250 Million
Day One Biopharmaceuticals announced preliminary net product revenue of $155.4 million for 2025, a 172% year-over-year increase, and projects 2026 revenue for OJEMDA to be between $225 million and $250 million. This growth is attributed to increased patient demand and the strategic acquisition of Mersana. The company maintains a strong financial position with approximately $441 million in cash and investments and will present its corporate progress at the J.P. Morgan Healthcare Conference on January 12, 2026.
Cancer drug OJEMDA sales jump 172% in 2025 as Day One sets 2026 target
Day One Biopharmaceuticals (DAWN) reported strong preliminary unaudited OJEMDA net product revenue of $155.4 million for 2025, marking a 172% year-over-year increase, with Q4 2025 revenue at $52.8 million. The company provided 2026 U.S. net product revenue guidance for OJEMDA between $225 million and $250 million and announced key pipeline milestones for Emi-Le and DAY301. Following this news, DAWN's stock surged over 25%, reflecting a significant positive market reaction.
Day One Announces Preliminary 2025 OJEMDA™ Net Product
Day One Biopharmaceuticals announced preliminary unaudited 2025 OJEMDA™ net product revenue of $155.4 million, reflecting 172% year-over-year growth. The company projects 2026 U.S. net product revenue for OJEMDA to be between $225 million and $250 million. These figures were released ahead of their presentation at the J.P. Morgan Healthcare Conference, where they will discuss corporate progress and 2026 priorities, including advancing pipeline programs like Emi-Le and DAY301.
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics to Enhance Oncology Pipeline
Day One Biopharmaceuticals has completed its acquisition of Mersana Therapeutics for $25 per share in cash plus a contingent value right. This acquisition strengthens Day One's oncology pipeline, particularly with Emi-Le, a novel antibody-drug conjugate targeting adenoid cystic carcinoma, allowing the company to expand its focus on adult and rare cancers. Mersana's common stock will be delisted from Nasdaq following the transaction.
Day One Biopharmaceuticals Signs Contingent Value Rights Agreement With Computershare
Day One Biopharmaceuticals has entered into a Contingent Value Rights (CVR) Agreement with Computershare to manage milestone-based cash payments related to the development and commercialization of emiltatug ledadotin (Emi-Le) following its acquisition of Mersana. These CVRs are generally non-transferable and involve potential payments triggered by FDA designations, approvals, initial commercial sales in key regions, and specific annual net sales thresholds until December 31, 2037. Computershare will serve as the rights agent and maintain the CVR holder registry, aligning acquisition consideration with Emi-Le's development and sales milestones.
Day One Completes Acquisition of Mersana Therapeutics
Day One Biopharmaceuticals, Inc. has successfully acquired Mersana Therapeutics, Inc. for $25 per share in cash plus one non-tradable contingent value right (CVR) per share for potential milestone payments. This acquisition expands Day One’s pipeline with emiltatug ledadotin (Emi-Le), a clinical-stage antibody drug conjugate targeting adenoid cystic carcinoma (ACC), a rare cancer. The deal aims to strengthen Day One's position in adult oncology and rare cancers, building on the momentum of its existing therapies.
Day One Completes Acquisition of Mersana Therapeutics
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) has successfully completed its acquisition of Mersana Therapeutics, Inc. (NASDAQ: MRSN). The acquisition involved a tender offer of $25 per share in cash plus one non-tradable contingent value right (CVR) per share for potential milestone payments. This strategic move expands Day One's pipeline into adult oncology with the addition of Emi-Le (emiltatug ledadotin), a novel ADC for adenoid cystic carcinoma (ACC).
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Nine analysts have given Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) an average rating of "Moderate Buy," with an average one-year price target of $24.43. Recent insider selling saw 28,001 shares sold, valued at $249,489, though insiders still own 6.20% and institutions own 87.95% of the stock. Despite a 57.6% year-over-year revenue decline, the company beat EPS estimates, posting -$0.19 against a -$0.28 estimate.
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth
Day One Biopharmaceuticals (NASDAQ:DAWN) has a cash runway of about 3.6 years from September 2025, with US$452m in cash and no debt. The company reduced its cash burn by 23% last year while increasing operating revenue by 31%, and analysts expect it to reach cashflow breakeven before exhausting its cash. With a market capitalization of US$899m and a cash burn of US$125m, the company could easily raise more capital if needed without significant dilution.
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 6% - What's Next?
Day One Biopharmaceuticals (NASDAQ:DAWN) experienced a 6% drop in its stock price during mid-day trading on Friday, despite generally positive analyst sentiment. The company reported mixed Q3 fundamentals, with an EPS beat and revenue exceeding estimates but a significant year-over-year revenue decline and negative net margin. Insider selling has also been noted recently, with CEO and other insiders selling approximately 28,001 shares in the last 90 days.
Day One Biopharmaceuticals Reports Promising FIREFLY-1 Trial Results
Day One Biopharmaceuticals Inc. has seen a 15.81% stock increase following promising three-year follow-up data from its FIREFLY-1 trial for tovorafenib, a pediatric low-grade glioma treatment. The positive clinical results are boosting investor confidence and positioning the company for potential commercial success in the competitive oncology market. Despite operational expenditures, the company maintains a strong financial outlook with a robust current ratio and impressive gross margin.
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 5.5% - Still a Buy?
Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) traded up 5.5% during mid-day trading, reaching $8.71 on increased volume. Despite weak fundamentals like a negative net margin and P/E, analysts maintain a "Moderate Buy" consensus with an average price target of $24.43. Recent insider selling has occurred amidst high institutional ownership.
Day One Biopharma (DAWN) Announces Positive 3-Year Follow-up Results from Pivotal Phase 2 FIREFLY-1 Trial of OJEMDA (Tovorafenib)
Day One Biopharmaceuticals Inc. (NASDAQ: DAWN) announced positive 3-year follow-up results from its pivotal Phase 2 FIREFLY-1 trial of OJEMDA (tovorafenib), a Type II RAF kinase inhibitor approved for pediatric low-grade glioma. The updated data, with a median study duration of 40.6 months, showed no new safety signals. JonesTrading analyst Soumit Roy maintained a Buy rating on the stock.
Hudson Bay Capital Management LP Has $8.43 Million Holdings in Day One Biopharmaceuticals, Inc. $DAWN
Hudson Bay Capital Management LP has increased its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 12.7%, now holding 1,296,700 shares valued at $8.43 million, contributing to institutional investors owning approximately 87.95% of the stock. Despite this, company insiders have recently sold shares, totaling $249,489 in the last three months. The company beat EPS estimates but saw a 57.6% year-over-year revenue decline and has a consensus "Moderate Buy" rating from analysts with a target price of $24.43.
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) announced that CEO Dr. Jeremy Bender will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12. The presentation will be webcast live on the company's website. Day One Biopharmaceuticals focuses on developing targeted therapies for life-threatening diseases, particularly pediatric cancer.
